Supreme Court Slims Down the Induced Infringement Cause of Action for Skinny Labels: Implications of Hikma Pharmaceuticals on Life Sciences Innovators

Introduction

In its recent decision in Hikma Pharmaceuticals USA v. Amarin Pharma Inc.,¹ the Supreme Court clarified the standard for surviving a motion to dismiss for innovator pharmaceutical companies seeking to allege that a generic product’s label-adjacent communications amount to induced infringement of unexpired method of use patents following the generic’s approval with a “skinny label.” In Hikma Pharmaceuticals, the Court unanimously held that Amarin Pharma, a branded pharmaceutical company, failed to state a claim for induced infringement where it alleged only that a generic manufacturer’s routine labeling, press releases, and marketing statements could be read as encouraging the carved-out patented uses, without plausibly alleging that Hikma actively encouraged those uses.

The decision settled a years-long circuit question on what counts as actionable inducement in the skinny label context, with implications for innovative and generic companies and investors in the life sciences industry as well as implications in other patent-heavy industries, such as healthcare and electronics. 

This article examines what the Hikma Pharmaceuticals case decided, what it left open, and what it means for branded and generic companies alike and for induced infringement cases generally.

Skinny Labels: What They Are and Why They Matter

A generic drug cannot compete with a patented brand-name drug during the relevant patent term unless the generic can successfully challenge the relevant patent’s validity, enforceability, or scope. If a product is approved in multiple different indications, some but not all of those approved indications may be protected by patents. Congress addressed this in the Hatch-Waxman Act of 1984 by creating the section viii statement, which allows generic manufacturers to seek FDA approval for only the unpatented indications while “carving out” still-patented uses from their labeling. The resulting “skinny label” works like a menu with certain dishes blacked out: the generic product can have a label showing that it is indicated only for unpatented indications.

Under the regulation, a generic manufacturer files a section viii statement certifying that it seeks approval only for unpatented indications. However, generic labeling is also governed by a “duty of sameness,” creating tension when portions of the innovator’s label must be carved out.

The Structural Tension: Hatch-Waxman vs. Induced Infringement

The Hatch-Waxman skinny-label regulations inherently create tension with patent law’s induced infringement doctrine because they authorize carveouts to enable generic competition for unpatented uses in a context in which the generic product will almost certainly also be used for a patented indication.² In particular, state pharmacy substitution laws allow, and sometimes require, cross-indication dispensing once the FDA provides the generic drug with an “AB” rating, which indicates that the generic drug is a therapeutic equivalent to the innovator drug and can be safely substituted for it.³ Meanwhile, patent law imposes liability on anyone who “actively induces infringement of a patent.”⁴ Legislative proposals like S. 43 (the “Skinny Labels Big Savings” Act) would create a statutory safe harbor for contributory infringement claims in the skinny-label context, but remain pending.⁵/p>

Factual Background: Vascepa, Icosapent Ethyl, and the Road to the Supreme Court

Amarin Pharma first developed Vascepa (icosapent ethyl) for severe hypertriglyceridemia (the “SH indication”), and it was approved for that indication in 2012.⁶ In 2019, FDA approved Vascepa for a second, more commercially significant use: reducing cardiovascular risk (the “CV indication”).⁷ Amarin obtained method-of-use patents for the CV indication.⁸

Hikma Pharmaceuticals submitted an ANDA for generic icosapent ethyl in 2016. After a district court invalidated Amarin’s SH-indication patents, Hikma supplemented its ANDA with a section viii statement, seeking a skinny label limited to the SH indication. In 2020, FDA approved Hikma’s skinny label limited application with an “AB” rating.⁹

Amarin filed suit in the District of Delaware, alleging that Hikma’s labeling, press releases, and marketing materials induced infringement of the CV-indication patents.¹⁰ The district court dismissed under Rule 12(b)(6), the Federal Circuit reversed in June 2024, and the Supreme Court granted certiorari in January 2026.¹¹

From GSK v. Teva to Hikma Pharmaceuticals

Understanding Hikma Pharmaceuticals requires tracing the Federal Circuit’s decade-long effort to define skinny label inducement, a doctrinal path that involved extensive fine-tuning. The arc begins with GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., ¹² where the Federal Circuit affirmed a $235 million jury verdict against Teva for inducing infringement of GSK’s patents on carvedilol for congestive heart failure, the carved-out indication.¹³ The decision suggested that routine generic labeling and marketing could support an inducement finding in this context.¹⁴

The Supreme Court denied certiorari in the GlaxoSmithKline case, with Justice Kavanaugh dissenting.¹⁵ Nevertheless, the Federal Circuit appeared to recalibrate in H. Lundbeck A/S v. Lupin Ltd,¹⁶ finding no liability for a generic product company that followed carveout rules and produced no promotional materials encouraging the patented use.¹⁷

Then in 2024, in Amarin v. Hikma Pharmaceuticals, a Federal Circuit panel reversed the district court’s finding that Amarin failed to state a viable claim for induced infringement, holding that the “totality” of Hikma’s statements plausibly alleged inducement.¹⁸ This decision prompted speculation that skinny label litigation would be permitted to proceed past the pleading stage in virtually every case.

The Supreme Court’s Decision

The Supreme Court unanimously reversed the Federal Circuit. Justice Jackson, writing for the Court, held that “the key question is whether a defendant actively encouraged infringement through its statements, not merely how others may understand those statements.”¹⁹ Analyzing the established elements of induced infringement and Amarin’s pleadings, the Court found that Amarin’s allegations made liability merely possible, but not plausible, as is required by applicable pleading standards to survive a motion to dismiss.

The Court identified three types of allegations that fall short of plausibility. First, statements with an “obvious alternative explanation” cannot support an inference of inducement when the non-infringing explanation is at least as likely as the infringing one.²⁰ Hikma’s references to therapeutic equivalence and its AB rating, the Court found, were precisely this type of statement: required or expected under FDA regulation and industry convention, not probative of intent to encourage patented uses.²¹

Second, “mere omissions, inactions, or nonfeasance” cannot constitute inducement. Amarin argued that Hikma’s failure to affirmatively disclaim the CV indication, or to instruct physicians not to prescribe for patented uses, supported an inference of inducement.²² The Court disagreed: inducement requires affirmative conduct, and the absence of a disclaimer is not the same as the presence of encouragement. Citing Twitter, Inc. v. Taamneh, the Court emphasized that secondary liability doctrines require “active” participation, not passive awareness that infringement may occur.²³

Third, “vague statements combined with speculation” cannot satisfy Iqbal’s demand for factual content. Amarin’s allegations that Hikma’s statements “could be read” as encouraging use of the generic product to treat the CV indication, or that physicians “might infer” encouragement from the totality of Hikma’s communications, amounted to speculation dressed as inference. The Court noted that MGM Studios Inc. v. Grokster, Ltd. held that inducement requires “clear expression or other affirmative steps” to foster infringement—a standard that Amarin’s complaint did not meet.

The Court, however, rejected Hikma’s argument that inducement must be “express.”²⁴ Therefore, implicit encouragement remains actionable when it is “clear to the relevant audience and affirmative.”²⁵ Future cases will undoubtedly explore these and other lines of conduct, whether in the generic drug context or in other contexts where induced infringement is a theory of liability.

In a significant footnote, the Court expressly criticized the Federal Circuit’s recent “trend” of focusing on how statements “could be read by medical providers” rather than whether the defendant actively encouraged infringement.²⁶ This inverts the inducement inquiry: the question is not what a physician might infer, but what the generic company in fact communicated.

The Court’s reasoning in Hikma Pharmaceuticals was consistent with (and cited to) its March 2026 decision in Cox Communications, Inc. v. Sony Music Entertainment, which addressed contributory copyright infringement and similarly emphasized that mere knowledge of infringing potential is insufficient to establish secondary liability.²⁷ Together, these decisions clarify certain boundaries for secondary liability claims across intellectual property law.

Key Takeaways for Innovative and Generic Pharmaceutical Companies

Hikma Pharmaceuticals confirms that standard labeling, AB-rating references, and “generic equivalent” descriptions alone likely will not provide a sufficient basis to survive a motion to dismiss in the skinny label context. However, the decision does not create a safe harbor; implicit encouragement remains actionable.

For branded companies, the decision clarifies the pleading bar. Future cases in this and other contexts will likely focus on other types of explicit and implicit actions and how they support the conclusion, alone or in the aggregate, that inducement is not merely possible but plausible.

For questions regarding the matters discussed in this article, please contact the authors or your usual Ropes & Gray advisor.